ProfileGDS5678 / 1452862_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 17% 18% 17% 2% 31% 12% 20% 17% 18% 15% 24% 18% 21% 17% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.429517
GSM967853U87-EV human glioblastoma xenograft - Control 22.4246218
GSM967854U87-EV human glioblastoma xenograft - Control 32.4230617
GSM967855U87-EV human glioblastoma xenograft - Control 41.872652
GSM967856U87-EV human glioblastoma xenograft - Control 52.6477331
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.3560412
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.5145820
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.4058917
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.4016818
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.3715515
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.550424
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.4030418
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.4957121
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.4167917